These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 3114883)

  • 1. Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties.
    Lijnen HR; Stump DC; Collen DC
    Semin Thromb Hemost; 1987 Apr; 13(2):152-9. PubMed ID: 3114883
    [No Abstract]   [Full Text] [Related]  

  • 2. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 3. Thrombolytic therapy in the eighties.
    Verstraete M; Collen D
    Blood; 1986 Jun; 67(6):1529-41. PubMed ID: 2423156
    [No Abstract]   [Full Text] [Related]  

  • 4. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tissue plasminogen activator: mechanism of action and thrombolytic properties].
    Páramo JA; Collen D
    Sangre (Barc); 1984; 29(4-C):767-73. PubMed ID: 6393389
    [No Abstract]   [Full Text] [Related]  

  • 6. Potentiation of the thrombolytic efficacy of single-chain urokinase (Pro-urokinase) by heparin.
    Gulba DC; Fischer K; Reil GH; Daniel WG; Lichtlen PR
    Thromb Haemost; 1988 Oct; 60(2):350-1. PubMed ID: 3146150
    [No Abstract]   [Full Text] [Related]  

  • 7. Thrombolytic treatment in acute myocardial infarction.
    Acar J; Vahanian A; Michel PL; Slama M; Cormier B; Roger V
    Semin Thromb Hemost; 1987 Apr; 13(2):186-200. PubMed ID: 2957791
    [No Abstract]   [Full Text] [Related]  

  • 8. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
    Czyrski J
    Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Holmes WE; Collen D
    J Biol Chem; 1988 Apr; 263(12):5594-8. PubMed ID: 2965704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrin binding and zymogenic properties of single-chain urokinase (pro-urokinase).
    Gurewich V; Pannell R
    Semin Thromb Hemost; 1987 Apr; 13(2):146-51. PubMed ID: 3114882
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular mechanism of action of newer thrombolytic agents.
    Collen D
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):11B-15B. PubMed ID: 3117858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
    Bachmann F
    Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 15. Newer thrombolytic drugs for acute myocardial infarction.
    Reddy DS
    Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombolytic therapy in acute myocardial infarct].
    Bode C; Baumann H; von Hodenberg E; Kübler W
    Med Klin (Munich); 1992 Feb; 87(2):64-9. PubMed ID: 1542285
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
    Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
    Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular mechanisms of thrombolytic therapy].
    Lijnen HR; Collen D
    Haemostasis; 1986; 16 Suppl 4():3-15. PubMed ID: 2945768
    [No Abstract]   [Full Text] [Related]  

  • 19. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F; Jang IK; Collen D
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches to thrombolytic therapy.
    Collen D; Lijnen HR
    Arteriosclerosis; 1984; 4(6):579-85. PubMed ID: 6439177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.